First approved in 2017, Dupixent is available as an injection in a prefilled pen. It will be used as an add-on maintenance treatment for adults whose COPD is not well controlled with inhalers.

In 2024, Dupixent became the first of these medicines ... which is called rotating the injection site. For example, the medicine can be injected into different parts of the thigh, stomach ...

Global healthcare company Sanofi and Regeneron Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injection to patients suffering from ...

Dupixent is intended for injection under the skin (subcutaneous injection) and is given every other week. It can be given in a clinic or at home by self-administration after training by a ...

12, 2024 /CNW/ - Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT ® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with ...

The most common adverse events in the Dupixent group included injection site reactions, accidental overdose, and COVID-19 infection. Regeneron and Sanofi plan to resubmit regulatory filings for ...

Safety results in both trials were generally consistent with the known safety profile of Dupixent in its approved indications. The most common side effects across indications include injection ...

12, 2024 /CNW/ - Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT ® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg ...

AEs more commonly observed with Dupixent (≥5%) compared to placebo included injection site reactions (12% vs. 4%), accidental overdose (7% vs. 3%) and COVID-19 infection (8% vs. 5%). Dupixent ...

AEs more commonly observed with Dupixent compared to placebo included injection site reactions, accidental overdose and COVID-19 infection. Dupixent has been approved for CSU in Japan, the United ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

AEs more commonly observed with Dupixent (=5%) compared to placebo included injection site reactions (12% vs. 4%), accidental overdose (7% vs. 3%) and COVID-19 infection (8% vs. 5%). Dupixent has ...